Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mamoru Hashimoto

Showing results (191-200 of 195) with videos related to

Pageof 20
Sort By:
You have reached the last page of results.This site can display upto 195 results.
Heliyon|November 25, 2024
Perceptual constancy of pareidolias across paper and digital testing formats in neurodegenerative diseasesGajanan S Revankar, Tatsuhiko Ozono, Maki Suzuki, et al.
Targeted Oncology|May 28, 2024
C-Reactive Protein-Albumin Ratio Predicts Objective Response to Enfortumab Vedotin in Metastatic Urothelial CarcinomaTaizo Uchimoto, Takuya Matsuda, Kazumasa Komura, et al.
Targeted Oncology|March 28, 2024
Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint InhibitorsTaizo Uchimoto, Shuya Tsuchida, Kazumasa Komura, et al.
International Journal of Clinical Oncology|January 31, 2025
Association of body mass index and tumor response in metastatic urothelial carcinoma treated with enfortumab vedotin: data from the ULTRA-Japan consortiumTaizo Uchimoto, Kengo Iwatsuki, Kazumasa Komura, et al.
International Psychogeriatrics|May 1, 2025
Nation-wide Japanese FTD consortium FTLD-J: Utility of case review meetingsShunsuke Sato, Kohji Mori, Michihito Masuda, et al.
Pageof 20

Showing results (191-200 of 195) with videos related to

Sort By:
Pageof 20
You have reached the last page of results.This site can display upto 195 results.
Heliyon|November 25, 2024
Perceptual constancy of pareidolias across paper and digital testing formats in neurodegenerative diseasesGajanan S Revankar, Tatsuhiko Ozono, Maki Suzuki, et al.
Targeted Oncology|May 28, 2024
C-Reactive Protein-Albumin Ratio Predicts Objective Response to Enfortumab Vedotin in Metastatic Urothelial CarcinomaTaizo Uchimoto, Takuya Matsuda, Kazumasa Komura, et al.
Targeted Oncology|March 28, 2024
Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint InhibitorsTaizo Uchimoto, Shuya Tsuchida, Kazumasa Komura, et al.
International Journal of Clinical Oncology|January 31, 2025
Association of body mass index and tumor response in metastatic urothelial carcinoma treated with enfortumab vedotin: data from the ULTRA-Japan consortiumTaizo Uchimoto, Kengo Iwatsuki, Kazumasa Komura, et al.
International Psychogeriatrics|May 1, 2025
Nation-wide Japanese FTD consortium FTLD-J: Utility of case review meetingsShunsuke Sato, Kohji Mori, Michihito Masuda, et al.
Pageof 20